StockData

Fate Therapeutics vs Ocugen

FATE and OCGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

fateFate Therapeutics$1.34+19.6% in 1 yearocgnOcugen$0.87−34.3% in 1 year

How FATE and OCGN compare

Ocugen is the larger company, worth 1.8 times as much as Fate Therapeutics ($296M against $161M).

Fate Therapeutics scores higher on the StockData Score (6 against 1 for Ocugen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFATEOCGN
Size and price
Market cap$161M$296M
Share price$1.34$0.874
Change, 1 year19.6%−34.3%
Change, 5 years−97.6%−88.7%
Beta (5Y)2.401.65
Employees161116
StockData Score
Total score6 (better)1
Valuation score1 (better)0
Growth score01 (better)
Performance score00
Health score5 (better)0
Dividend score00
Valuation
P/S33.8×–
P/B1.2×–
FCF yield−66.5%−21.6% (better)
Fair value$1.13–
Margin of safety−18.6%–
Growth
Revenue growth (TTM)−33.4%–
Revenue growth, 5Y average−26.7%152% (better)
Profitability
Operating margin−2760%–
Net margin−2620%–
FCF margin−2249%–
Return on equity−67.8%–
Return on invested capital−1647%–
Financial health
Debt / equity0.00–
Interest coverage–−6.8×
Current ratio4.41 (better)0.77
Altman Z-score−9.87−6.90 (better)
Piotroski F-score3 (better)0
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions59.9%42.8%
Held by insiders25.7%2.4%
Insider net buying, 12 months−$336K (better)−$1.1M
Short interest, % of float11.2%32.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.